Serum free IgE guided dose reduction of omalizumab: a case report
Serum free IgE guided dose reduction of omalizumab: a case report
About this item
Full title
Serum free IgE guided dose reduction of omalizumab: a case report
Author / Creator
Journal title
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2017, Vol.13, p.39-39
Language
English
Formats
More information
Scope and Contents
Contents
BACKGROUNDOmalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for severe asthma patients who are allergic to perennial allergens. The effects of omalizumab for severe...
Alternative Titles
Full title
Serum free IgE guided dose reduction of omalizumab: a case report
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1936162466
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1936162466
Other Identifiers
ISSN
1710-1484
DOI
10.1186/s13223-017-0211-z
How to access this item
Log in as a Library member
